Changes in renal function following nedaplatin‑containing chemotherapy in patients with urothelial carcinoma unfit for cisplatin

Abstract

The present study evaluated the impact of nedaplatin-containing chemotherapy on renal function in 35 patients with urothelial carcinoma (UC) between 2001 and 2014 who were unfit for cisplatin treatment. As comparative controls, the present study also examined 35 patients with the same disease who underwent cisplatin-containing chemotherapy during the same period. The changes in the estimated glomerular filtration rate (eGFR) prior to and following the administration of nedaplatin during each cycle of chemotherapy was investigated. The present study also reported the overall response rates and adverse events in each group. A total of 31 cycles of the gemcitabine/nedaplatin regimen and 66 cycles of the methotrexate/epirubicin/nedaplatin regimen were administered. In the nedaplatin group, the mean eGFRs prior to and following chemotherapy were 45.4 and 47.8 ml/min/1.73 m 2 , respectively. The eGFR of the post-chemotherapy group was significantly increased (P<0.001). On the other hand, in the cisplatin group, the eGFR following chemotherapy was significantly lower than the rate prior to chemotherapy (P<0.001). The overall response rates were 30.4 and 66.7% in the nedaplatin and cisplatin groups, respectively. In the two groups, myelosuppression was the most common side effect, but the occurrence rates in both groups were similar, and these adverse events were manageable. With regard to nephrotoxicity, nedaplatin-containing chemotherapy for cisplatin-unfit patients with UC is a safe treatment modality.

Anticancer maintenance chemotherapy prolonged prognosis of metastatic urothelial carcinoma patients: A single institute retrospective study using propensity score matching

“…Nedaplatin is more soluble than cisplatin and has fewer side-effects in relation to renal function and gastrointestinal symptoms. 19,20 In our institute, we treat cisplatin-unfit patients with mUC using a GN regimen that includes nedaplatin instead of carboplatin. The prognosis of patients with mUC is poor, and various methods such as immunotherapy alone or combined chemotherapy and immunotherapy have been attempted to improve the prognosis.…”

“…To our knowledge, no standard chemotherapy for cisplatin‐unfit patients has been established. Nedaplatin is more soluble than cisplatin and has fewer side‐effects in relation to renal function and gastrointestinal symptoms 19,20 . In our institute, we treat cisplatin‐unfit patients with mUC using a GN regimen that includes nedaplatin instead of carboplatin.…”